KV Pharmaceutical Company Announces NYSE Listing Extension (The San Francisco Examiner)
ST. LOUIS , Dec. 28 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE: KVa/KVb) a fully integrated specialty pharmaceutical company that develops, manufactures, acquires and markets technology differentiated branded and generic/non-branded prescription pharmaceutical products, announced today that NYSE Regulation, Inc. has granted KV's request for a trading extension through February 15, ...

Theravance Receives Notice of Possible Telavancin Review by FDA Advisory Committee (Marketwire via Yahoo! Finance)
Theravance, Inc. today announced that it has received notice from the U.S. Food and Drug Administration that the agency's Anti-Infective Drugs Advisory Committee may soon meet to review the NDA for telavancin, a novel, bactericidal, once-daily injectable antibiotic proposed to treat complicated skin and skin structure infections caused by Gram-positive bacteria, including resistant pathogens ...